CuraVac is a clinical-stage biotech company developing Therapeutic Vaccines and Active Targeted Immunotherapies for autoimmune diseases. With the use of a new revolutionary technique based on complementary peptides, we aim to induce long-term immunity against autoimmune diseases such as Multiple Sclerosis (MS), Myasthenia Gravis (MG), diabetes, Graves’ disease, Systemic Lupus Erythematosus (SLE) and Hashimoto’s disease.
CuraVac’s lead candidate therapeutic vaccine for myasthenia gravis, CV-MG, has already completed the clinical study phase 1B with an excellent safety profile.
We are curently preparing a phase 2 efficacy demonstration clinical trial.
CuraVac’s CV-MG is a potential breakthrough in MG treatments and a potential therapeutic revolution for all autoimmune diseases – being the first to possibly bring a long-lasting improvement and a potential cure to patients.